AXIOS Sustainable Growth Acquisition Corp. (NYSE:AXAC) announced in an 8-K this afternoon that it has signed non-redemption agreements with one or more third parties.
The investors hold an aggregate of 400,000 shares of common stock and have agreed to not redeem their shares at AXAC’s upcoming extension meeting on February 14. The SPAC, which IPO’d in February 2022, has a completion deadline approaching on February 18, but is hoping to gain shareholder approval to extend its timeline to February 2024.
Pursuant to the non-redemption agreements, the shareholders have agreed to vote in favor of the extension proposal. Additionally, AXIOS expects the agreements to increase the amount of funds that remain in its trust account following the meeting.
The agreements provide for the allocation of one share of AXAC common stock held by its sponsor in exchange for each five public shares the investor agrees to hold and not redeem.
AXIOS Sustainable Growth raised $150 million in its IPO and is still on the hunt for a target company. It intends to acquire a business engaged in agribusiness, plant-based proteins, food processing and AgTech based in Central and Eastern Europe.
The SPAC and its sponsor expect to execute additional non-redemption agreements with other investors prior to its meeting next week.
New Providence Acquisition Corp. III (NASDAQ:NPACU) announced the pricing of its $261 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “NPACU”, Thursday, April 24, 2025. The new SPAC aims to combine with a consumer target that has the potential to generate attractive risk-adjusted returns. New Providence III’s...
Cantor Equity Partners Inc. (NASDAQ:CEP) has entered into a definitive agreement to combine with Twenty One Capital at an enterprise value of $3.6 billion, or 1x its future net asset value (NAV). Twenty One Capital aims to secure a sizeable Bitcoin holding and leverage it for financial services products as well as Bitcoin-focused media offerings....
Voyager (NASDAQ:VACH) has signed a definitive agreement to combine with biotech firm VERAXA at an enterprise value of $1.38 billion. Heidelberg, Germany-based VERAXA is developing cancer treatments with its most advanced candidate targeting acute myeloid leukemia (AML). The combined company is expected to trade on the Nasdaq under the symbol “VERX” once the deal is...
At the SPAC of Dawn SPACs announced two more business combinations and priced a IPO in the past 24 hours showing that activity is going to continue apace regardless of the present market volatility. Another major deal is rumored in the wind with Cantor Equity Partners I (NASDAQ:CEPO) reportedly nearing a major merger that would...
Texas Ventures Acquisition III Corp (NASDAQ:TVACU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “TVACU”, Wednesday, April 23, 2025. The new SPAC’s primary search focus will be on industrial technology, specifically companies implementing advanced technologies including software, mobile and IoT applications,...